Manufacturing of cancer drug Trodelvy will be moved to Oceanside, California as part of a restructuring of Gilead Science’s New Jersey operations. In September 2020, Gilead paid $21 billion to acquire Immunomedics. The deal added antibody-drug conjugate (ADC) Trodelvy (sacitizumab govitecan) – approved in April 2020 to treat triple negative breast cancer – to Gilead’s portfolio, along with an biomanufacturing facility in Morris Plains, New Jersey. But plans to create a corporate hub in Northern New Jersey will result in…